A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.

rLj-RGD3, a new member of the RGD (Arginine-Glycine-Aspartate)-motif toxin protein family obtained from Lampetra japonica by means of recombinant DNA techniques, has been demonstrated to be a platelet fibrinogen receptor antagonist and holds potential as a drug candidate for a specific indication. T...

Full description

Bibliographic Details
Main Authors: Yuping Wang, Zhien Liu, Guozhu Han, Ping Yu, Xiaobo Yang, Jihong Wang, Li Lv
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-08-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0011568
_version_ 1797667818801463296
author Yuping Wang
Zhien Liu
Guozhu Han
Ping Yu
Xiaobo Yang
Jihong Wang
Li Lv
author_facet Yuping Wang
Zhien Liu
Guozhu Han
Ping Yu
Xiaobo Yang
Jihong Wang
Li Lv
author_sort Yuping Wang
collection DOAJ
description rLj-RGD3, a new member of the RGD (Arginine-Glycine-Aspartate)-motif toxin protein family obtained from Lampetra japonica by means of recombinant DNA techniques, has been demonstrated to be a platelet fibrinogen receptor antagonist and holds potential as a drug candidate for a specific indication. The present article reports an innovative validated highly sensitive and specific biotin-avidin enzyme linked immunosorbent assay (BA-ELISA) to provide a bio-analytical method for pharmacokinetic (PK) studies of rLj-RGD3. The concentration of picogram level rLj-RGD3 in rat plasma was measured using the developed double sandwich BA-ELISA assay, which used two mouse anti-rLj-RGD3 monoclonal antibodies that recognize different epitopes for capture and detection. This method was verified to be highly specific (blank plasma did not interfere with detection), precise (RSD <15%), and accurate (86%-113%). Absolute recovery was in the 94%-119% range. The calibration curve showed good linearity within the 50 to 1600 pg/mL range. The LOQ was as low as 50 pg/mL. The above validated assay was successfully employed to assess PK of rLj-RGD3 in rats. After i.v. and s.c. dosing with 30 μg/kg, the rLj-RGD3 plasma concentration declined bi-exponentially with time. This decay was best fitted to a two-compartment model. In conclusion, the BA-ELISA method described here meets all requirements for PK studies of rLj-RGD3 with an effective pharmacological dose in the μg/kg BW range.
first_indexed 2024-03-11T20:20:05Z
format Article
id doaj.art-16656787244a43629942928254dbb3e0
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-03-11T20:20:05Z
publishDate 2023-08-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-16656787244a43629942928254dbb3e02023-10-03T05:31:58ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352023-08-01178e001156810.1371/journal.pntd.0011568A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.Yuping WangZhien LiuGuozhu HanPing YuXiaobo YangJihong WangLi LvrLj-RGD3, a new member of the RGD (Arginine-Glycine-Aspartate)-motif toxin protein family obtained from Lampetra japonica by means of recombinant DNA techniques, has been demonstrated to be a platelet fibrinogen receptor antagonist and holds potential as a drug candidate for a specific indication. The present article reports an innovative validated highly sensitive and specific biotin-avidin enzyme linked immunosorbent assay (BA-ELISA) to provide a bio-analytical method for pharmacokinetic (PK) studies of rLj-RGD3. The concentration of picogram level rLj-RGD3 in rat plasma was measured using the developed double sandwich BA-ELISA assay, which used two mouse anti-rLj-RGD3 monoclonal antibodies that recognize different epitopes for capture and detection. This method was verified to be highly specific (blank plasma did not interfere with detection), precise (RSD <15%), and accurate (86%-113%). Absolute recovery was in the 94%-119% range. The calibration curve showed good linearity within the 50 to 1600 pg/mL range. The LOQ was as low as 50 pg/mL. The above validated assay was successfully employed to assess PK of rLj-RGD3 in rats. After i.v. and s.c. dosing with 30 μg/kg, the rLj-RGD3 plasma concentration declined bi-exponentially with time. This decay was best fitted to a two-compartment model. In conclusion, the BA-ELISA method described here meets all requirements for PK studies of rLj-RGD3 with an effective pharmacological dose in the μg/kg BW range.https://doi.org/10.1371/journal.pntd.0011568
spellingShingle Yuping Wang
Zhien Liu
Guozhu Han
Ping Yu
Xiaobo Yang
Jihong Wang
Li Lv
A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
PLoS Neglected Tropical Diseases
title A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
title_full A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
title_fullStr A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
title_full_unstemmed A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
title_short A picogram BA-ELISA quantification assay for rLj-RGD3, a platelet fibrinogen receptor antagonist, in the rat plasma and its application to a pharmacokinetic study.
title_sort picogram ba elisa quantification assay for rlj rgd3 a platelet fibrinogen receptor antagonist in the rat plasma and its application to a pharmacokinetic study
url https://doi.org/10.1371/journal.pntd.0011568
work_keys_str_mv AT yupingwang apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT zhienliu apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT guozhuhan apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT pingyu apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT xiaoboyang apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT jihongwang apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT lilv apicogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT yupingwang picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT zhienliu picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT guozhuhan picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT pingyu picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT xiaoboyang picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT jihongwang picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy
AT lilv picogrambaelisaquantificationassayforrljrgd3aplateletfibrinogenreceptorantagonistintheratplasmaanditsapplicationtoapharmacokineticstudy